Marvel Biosciences receives Japanese patent for MB-204

Executive Summary

• Marvel Biosciences received a Japanese patent (No. 2022-554855) for its lead therapeutic candidate, MB-204, covering composition of matter and methods of use.
• This marks the second major jurisdiction to grant a composition-of-matter patent for MB-204, strengthening the company's global intellectual property portfolio.
• MB-204 is a novel fluorinated analogue of istradefylline, currently showing robust preclinical efficacy in models of depression, autism (including Rett syndrome), and fragile X syndrome.

Key Details

• Patent Details: Japan Patent Office granted Japanese patent No. 2022-554855, titled "Purine Compounds for Treating Disorders."
• Scope: The patent covers composition of matter and methods of use claims for MB-204.
• Strategic Impact: CEO Rod Matheson stated this strengthens the global IP portfolio and enhances long-term value as the company advances toward clinical development.
• Drug Profile: MB-204 is a novel fluorinated analogue of istradefylline (an approved adenosine A2A receptor antagonist for Parkinson's disease).
• Preclinical Data:
  • Demonstrated improved pharmacokinetics relative to the parent compound.
  • Completed preclinical toxicology testing.
  • Showed robust preclinical efficacy in models of depression.
  • Showed efficacy in multiple models of autism, including Rett syndrome.
  • Currently being evaluated in fragile X syndrome models.
• Market Context: Autism spectrum disorder affects approximately one in 36 children by age eight. Marvel believes MB-204's differentiated profile and patent coverage position it for continued development and potential strategic partnerships.

Notable Quotes

• "This represents the second major jurisdiction to grant a composition-of-matter patent for our lead molecule MB-204. Securing patent protection in Japan significantly strengthens our global intellectual property portfolio and further enhances the long-term value of MB-204 as we advance toward clinical development." — Rod Matheson, Chief Executive Officer